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Background: The objective of the SCHLA-HF registry is to investigate the prevalence of sleep-disordered breathing
(SDB) in patients with chronic heart failure with reduced left ventricular systolic function (HF-REF) and to determine
predictors of SDB in such patients.
Methods: Cardiologists in private practices and in hospitals in Germany are asked to document patients with
HF-REF into the prospective SCHLA-HF registry if they meet predefined inclusion and exclusion criteria. Screening
was started in October 2007 and enrolment was completed at the end of May 2013. After enrolment in the registry,
patients are screened for SDB. SDB screening is mainly undertaken using the validated 2-channel ApneaLink™
device (nasal flow and pulse oximetry; ResMed Ltd., Sydney, Australia). Patients with a significant number of apneas
and hypopneas per hour recording time (AHI ≥15/h) and/or clinical symptoms suspicious of SDB will be referred
to a cooperating sleep clinic for an attended in-lab polysomnography with certified scoring where the definite
diagnosis and, if applicable, the differentiation between obstructive and central sleep apnea will be made.
Suggested treatment will be documented.
Discussion: Registries play an important role in facilitating advances in the understanding and management of
cardiovascular disease. The SCHLA-HF registry will provide consistent data on a large group of patients with HF-REF
that will help to answer questions on the prevalence, risk factors, gender differences and stability of SDB in these
patients by cross-sectional analyses. Further insight into the development of SDB will be gained by extension of the
registry to include longitudinal data.
Keywords: Registry, Prevalence, Heart failure, Sleep-disordered breathing, Obstructive sleep apnea,
Central sleep apnea, Cheyne-Stokes respiration, Predictors* Correspondence: michael.arzt@ukr.de
4Department of Internal Medicine II, University Hospital Regensburg,
Regensburg, Germany
8Schlafmedizinisches Zentrum, Klinik und Poliklinik für Innere Medizin II,
Universitätsklinikum Regensburg, Franz-Josef-Strauss-Allee 11, 93053
Regensburg, Germany
Full list of author information is available at the end of the article
© 2014 Woehrle et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Woehrle et al. BMC Cardiovascular Disorders 2014, 14:46 Page 2 of 7
http://www.biomedcentral.com/1471-2261/14/46Background
The prevalence of heart failure (HF) in western coun-
tries is about 1-2% of the adult population, with signifi-
cant increases as age increases [1,2]. Recent guidelines
differentiate between HF due to reduced systolic left
ventricular ejection fraction (HF-REF) and HF with pre-
served ejection fraction (HF-PEF) and impaired diastolic
function [3]. HF-REF is the most widely investigated and
best understood type of HF [3], with a high prevalence in
males with ischemic heart disease. In contrast, HF-PEF is
more prevalent in women and often has a non-ischemic
aetiology. Epidemiological data suggest that HF-REF and
HF-PEF have a similar prognostic impact [4].
A number of co-morbidities have been linked to the de-
velopment and progression of HF. One that is gaining in-
creasing recognition is sleep-disordered breathing (SDB)
with predominant obstructive (OSA) or central sleep
apnea (CSA) with or without Cheyne-Stokes respiration
(CSR). Small studies published to date have reported that
the prevalence of SDB was almost 70-80% in patients with
HF-PEF and up to 76% in those with HF-REF based on a
cut-off of an apnea-hypopnea index (apneas and hypopo-
neas per hour of recording time; AHI) ≥ 5/h while moder-
ate to severe sleep apnea with an AHI ≥ 15/h was
prevalent in about half of the patients [5-7].
The Sleep Heart Health Study identified OSA as an in-
dependent risk factor for the development of HF [8],
with more impact in men than in women [9]. Patients
with CSA have been shown to have a reduced quality of
life [10] and to be at increased risk of developing cardiac
arrhythmias [11]. In addition, the prevalence of CSA-
CSR appears to increase as the severity of HF increases
and cardiac function decreases [5,6]. Thus, the occur-
rence of CSA-CSR and its severity is thought to mirror
cardiac dysfunction [12,13]. In addition, SDB in general
[14], as well as OSA [15] and, in particular, CSA [16,17]
have been shown to be independently associated with
worse prognosis in patients with HF-REF. Even when
HF-REF patients are receiving optimal treatment of HF,
including cardiac resynchronization therapy (CRT), even
a low level of CSA-CSR or OSA appears to have a major
impact on prognosis [18].
Patient registries are increasingly being recognized as
an important source of data about the natural history of
disease, the effects of interventions or treatments, the
relationship between baseline variables and outcomes,
and the impact of risk factors [19-21]. Registries can also
generate hypotheses to be tested in future randomized
controlled clinical trials [19] and can serve as screening
instruments for randomized trials. In this paper, the
SCHLA-HF registry is introduced, which was started to
fulfil these needs simultaneously for SDB in HF. For ex-
ample, enrolment into the SCHLA-HF registry is a re-
quirement for patients to be recruited into the SERVE-HFstudy (‘Treatment of Predominant Central Sleep Apnea
by Adaptive Servo Ventilation in Patients with Heart
Failure’; NCT00733343) [22]. SERVE-HF is the first
multinational, multicentre, randomised, parallel trial to
assess the effects of the addition of adaptive servo-
ventilation (ASV) to optimal medical management com-
pared with medical management alone on prognosis in HF-
REF patients with predominant CSA. Its major substudy
(NCT01164592) [22] will investigate potential mechanisms
of benefit (e.g. reverse remodelling effects using echocardi-
ography or changes in sleep using PSG). As screening in-
strument, the SCHLA-HF registry will include thousands
of patients with stable HF-REF.
The objective of the registry is to investigate the preva-
lence of SDB in chronic HF-REF patients as well as risk
factors, gender differences and stability of SDB in such
patients. This report details data collection and assess-
ments that will be undertaken in patients prospectively
included in the SCHLA-HF registry.Methods
The SCHLA-HF registry received central ethics approval
from the Freiburger Ethikkomission for Germany. All as-
pects of the registry were conducted within the princi-
ples of Good Clinical Practice and in accordance with
the Declaration of Helsinki.Design of the registry
All German sleep laboratories were invited to participate
in the registry. However, the majority did not have the
infrastructure necessary to run such a project. Sleep la-
boratories were then asked to contact cardiologists in
their referral area to build networks between cardiology
and sleep medicine, which allowed the registry and the
SERVE-HF study to proceed. Participating cardiologists,
who had been contacted by and were working with sleep
laboratories, were asked to enroll consecutively all heart
failure patients who fulfilled the registry inclusion cri-
teria described below.
One hundred and thirty-eight centres in Germany (91
cardiology practices and 47 hospital cardiology depart-
ments) are testing patients with chronic HF-REF for eli-
gibility (patient flow diagram, Figure 1). After enrolment
in the registry, patients are screened for SDB. Patients
with a significant number of apneas and hypopneas per
hour recording time (AHIscreening ≥15/h) and/or clinical
symptoms suspicious of SDB will be referred to one of
the 66 cooperating sleep clinics for an attended in-lab
polysomnography (PSG) with certified scoring where the
definite diagnosis and will be made, and the suggested
treatment will be documented (Figure 1). The registry
was started in October 2007 and enrolment was com-
pleted at the end of May 2013. It is expected that data
Screened for eligibility
n=10,490





no SDB symptoms 
n=2,892 (42%)
AHI 15/h or AHI <15/h and symptoms of SDB
PSG
in lab with certified scoring n=3,984(58%)
Analysis  Population  II:n=2,365(59%)
Analysis  Population  III:n=1,808(76%)
Incomplete Dataset: n=1,609
PSG missing n=1,590 (40%), 
Incomplete Documentation n=29 (1%)
No or mild SDB (AHI<15/h) 
n=557 (24%)
Analysis Population I:  n=6876 (75%)
Screening for SDB 
(2-channel screening device [nasal flow and pulse oximetry]or polygraphy)
ApneaLink, n=5505 (80%); Mixed, n=718 (10%); PG centers, n=653 (10%)
Incomplete Dataset*: n=2,345
SDB Screening n=391, 
Gender n=0,
Chronic atrial fibrillation n=1,977, 
Age n=1, BMI n=1,
LVEF n=1,946, NYHA n=1,957,
Etiology n=1,930
Figure 1 Patient flow and populations in the SCHLA-HF registry. AHI, apnea-hypopnea index; BMI, body mass index; LVEF, left ventricular
ejection fraction; NYHA, New York Heart Association; PG, polygraphy; PSG, polysomnography; SDB, sleep-disordered breathing.
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report available in 2015.
Patients
For cardiologists screening patients, criteria for inclusion of
patients in the SCHLA-HF registry are as follows: chronic
HF diagnosed and treated according to the European Soci-
ety of Cardiology (ESC) guidelines [23] ≥12 weeks prior to
enrolment; moderate-to-severe left ventricular systolic dys-
function (left ventricular ejection fraction [LVEF] ≤45% by
an imaging method such as echocardiography, radionuclide
angiography, left ventriculography or cardiac magnetic
resonance imaging) documented <12 weeks before en-
rolment; New York Heart Association (NYHA) class III
or IV at the time of inclusion or NYHA class II with ≥1
hospitalisation for HF in the last 12 months; patient able
to fully understand study information and give signed
informed consent.
Patients are not eligible to be included in the registry
if the had any of the following: current use of positiveairway pressure (PAP) therapy; life expectancy <1 year for
diseases unrelated to chronic HF-REF; cardiac surgery,
percutaneous coronary intervention, myocardial infarction
or unstable angina within 6 months prior to randomisa-
tion; CRT-implantation scheduled or performed within
6 months prior to randomisation; transient ischemic at-
tack or stroke within 3 months prior to enrolment; pri-
mary hemodynamically-significant uncorrected valvular
heart disease (obstructive or regurgitant) or any valvular
disease expected to require surgery; acute myocarditis/
pericarditis within 6 months prior to enrolment.
Assessments
Demographic and clinical data
Demographic data, information about severity of HF-
REF (New York Heart Association functional class,
NYHA) and aetiology of HF-REF are assessed. In
addition, common comorbidities of HF-REF (atrial fibril-
lation and diabetes) and symptoms of HF-REF/SDB such
as nocturia, nap time, nocturnal dyspnea as well as
Woehrle et al. BMC Cardiovascular Disorders 2014, 14:46 Page 4 of 7
http://www.biomedcentral.com/1471-2261/14/46medication are documented. Documentation of LVEF
measured by an imaging method such as echocardiog-
raphy, radionuclide angiography, left ventriculography or
cardiac magnetic resonance imaging within 12 weeks
prior to enrolment was added when data collection was
expanded in May 2009, after 2395 patients had been en-
rolled. Also, the documentation of diabetes and heart
rhythm was added.
Screening for sleep-disordered breathing
After enrolment in the registry, SDB screening is then
undertaken mainly using the two channel screening sys-
tem ApneaLink™ (ResMed Ltd., Sydney, Australia) which
measures nasal flow via a cannula and records pulse oxim-
etry that has been validated in several studies for screening
of SDB [24–29]. The default settings of the screening de-
vice were used for the definitions of apnea, hypopnea and
desaturation: apnea was defined as an 80% decrease in air-
flow for ≥10 seconds; hypopnea was defined as a decrease
in airflow by 50-80% versus baseline for ≥10 seconds; de-
saturation was defined as a ≥4% decrease in oxygen satur-
ation; SDB in the screening process was defined as
AHIscreening ≥ 15/h.
In addition, the ApneaLink™ provides a flow-based
classifier as an automated diagnostic test for CSR. The
classifier of ApneaLink uses various features for identify-
ing CSR. The main features are the cycle length (for
CSR usually 45–90 s), the apnea-hypopnea length, the
hyperpnea length, and the shape of the hyperpnea as de-
scribed previously [30]. Of the 138 cardiology centres,
15 used respiratory polygraphy for screening of SDB, ei-
ther alone (n = 7) or in combination with ApneaLink™.
Apneas and hypopneas were defined and scored accord-
ing to the criteria above.
Patients with SDB or typical clinical symptoms are being
referred to a sleep laboratory where a polysomnography
(PSG) will be performed to make a definite diagnosis
of SDB.
Diagnosis of obstructive or central sleep apnea with or
without Cheyne-Stokes Respiration
PSG will contain brain activity (electro encephalogram,
EEG), eye movement (electro oculogram, EOG), muscle
activity or skeletal muscle activation (electro myogram,
EMG), heart rhythm (electro cardiogram, ECG), breath-
ing and respiratory effort measures during sleep as well
as the recording of body position. Flow measurement
has to be performed by nasal cannula and thermistor
during diagnostic procedures.
A standardized qualification process for each center has
been used to ensure comparability between centers in the
scoring of respiratory events. Prior to participation every
center had to send two diagnostic respiratory scorings to a
central lab that validated whether such scorings wereperformed according to a detailed operating manual for
technical requirements of PSG and respiratory scoring. If
quality was not acceptable, specific training was provided,
followed by another quality assessment. A key element of
the PSG scoring manual is the differentiation of apneas
and hypopneas as central or obstructive using flattening
of the inspiratory airflow curve, paradoxical breathing,
arousal position, sleep stages, and breathing pattern at the
end of the hypopnea [31,32].
Statistical considerations
Sample size
The sample size of the SCHLA-HF registry is linked to
the recruitment period of the SERVE-HF trial. No for-
mal sample size calculations were performed for the
registry. A total of three prespecified analysis datasets
have been defined (Figure 1): the “Screening Data Set”
(“Analysis Population I”), the “PSG Data Set” (Analysis
Population II) and the “PSG AHI ≥15 Data Set” (Ana-
lysis Population III). Numbers presented are those up to
end of May 2013 (Figure 1).
Statistical analysis
All variables will be analyzed using descriptive statistics
(frequency, mean ± standard deviation [SD], range or
median ± interquartile range, whichever is appropriate).
Student’s t-test will be used to compare mean values. A
Chi-square test will be used to compare frequencies and
proportions in two or more groups. Data will be used
for a nested case–control study comparing patients with
and without SDB (analysis population I) or patients with
different severity and type of SDB (analysis populations
II and III) with respect to their characteristics and his-
tory. Multivariate logistic regression modelling will be
used to analyze the associations between suspected
causes of SDB and the risk of developing that disorder
taking the cluster structure of the data entered by the
recruiting cardiologists into account. The models will in-
clude potential clinical predictors of SDB, or of the extent
of SDB, that are assessed in the SchlaHF registry such as
age, BMI, gender, LVEF, NYHA class, aetiology of HF, and
atrial fibrillation. Models will be fitted by likelihood ratio-
based stepwise backward variable selection. The predictive
accuracy of the resulting models will be judged by cross
validation. A p value of <0.05 is considered to be statis-
tically significant. Statistical analysis will be performed
with SPSS version 19.0 or higher (SPSS Inc., Chicago,
USA) or STATA 12.0 or higher (StataCorp LP, College
Station, Texas, USA).
Ethics and monitoring
The registry was approved by the local ethics committees
of the participating institutions and is being managed in ac-
cordance with Good Clinical Practice and the Declaration
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to be included in the registry. The patients are advised in
the consent forms that they have the right to withdraw
from the registry at any time without it impacting on their
treatment. In the event that a patient drops out of the regis-
try, a Registry Termination Form has to be completed,
which details the date of termination and reason for ter-
mination. The patient is also informed she/he must spe-
cifically request that her/his data will not be analysed.
Otherwise data remain in the database and will be included
in the analysis. Reasonable effort will be made to contact
any patient lost to follow-up (between SDB-screening and
PSG) in order to complete assessments and retrieve any
outstanding data.
Discussion
Data from both large-scale clinical trials and registries
have provided a large volume of data on patients with
cardiovascular disease. It is increasingly recognised that
large randomised, controlled clinical trials are extremely
expensive to perform and often generate results that
may not be generalizable to a wide population of pa-
tients in clinical practice [33]. Thus, the combination of
good quality clinical studies and prospective registries is
likely to be the best approach to identifying, defining
and applying treatments and strategies to improve pa-
tient outcomes [19].
The focus of the SCHLA-HF registry is SDB in pa-
tients with HF-REF. SDB is increasingly being recog-
nised as an independent risk factor for the development
of HF [8,9,14,34,35] and as making an important contri-
bution to worse outcomes in these patients [14-16]. In
addition, worsening HF appears to increase the inci-
dence and severity of SDB [5,6], while effective treat-
ment of SDB appears to improve clinical outcomes in
patients with HF [14,36].
One multicenter study and 5 single-center studies
with ≥100 participants provide estimates of SDB preva-
lence in HF-REF (Table 1) [6,37-42]. Previous studies con-
sistently indicate that the SDB is very common in HF.
However, the SCHLA-HF registry may overcome some
limitations of the previous studies. This will be achievedTable 1 Prevalence of sleep-disordered breathing in chronic h
Study Setting Total patients (n) Fe
Schulz et al. 2007 [37] Multicenter 203
Javaheri et al. 2006 [38] Single center 100
Oldenburg et al. 2007 [6] Single center 700
Sin et al. 1999 [39] Single center 450
Yumino et al. 2009 [40] Single center 218
Paulino et al. 2009 [41] Single center 316
Dolliner et al. 2013 [42] Single center 176
*reported prevalence of sleep-disordered breathing (SDB) based on a definition usiin a number of ways. Firstly, by including HF-REF patients
from a large number of cardiology practices or hospital car-
diology departments, the SCHLA-HF-registry will study a
more representative sample compared to studies from spe-
cialized hospital cardiology departments [6,38,40,41] or
sleep clinic populations [39] alone. Secondly, since the pro-
portion of women with both HF-REF and SDB was low in
previous studies, a very high total sample size, as targeted
in the SCHLA-HF registry, is required to provide robust
analyses of SDB prevalence and risk factors in women. Fi-
nally, in contrast to some of the previous studies [38-40],
patients of the SCHLA-HF registry will be on current med-
ical therapy for HF-REF.
Limitations
A multi-step procedure was established to improve the
representativeness of the registry and, in particular, to
capture as many SDB patients as possible, even if they
were not accurately diagnosed at their first visit. How-
ever, such a multi-step procedure can itself be a source
of bias. Perhaps the most important potential limitation
of this study is the interaction/collaboration between
cardiology physicians and the sleep laboratories. Such in-
teractions have the potential to introduce bias, and miss-
ing PSG results need to be taken into account when
interpreting the data.
Perspective
Effective management of SDB and associated improve-
ments in HF morbidity and mortality is a potential
approach to managing the many HF patients who re-
main symptomatic and have disease progression despite
guideline-driven pharmacological and device-based
therapy. It is hoped that data gathered by the SCHLA-
HF registry will make a substantial contribution to the
body of knowledge in the area of HF-REF and SDB. In
addition, it has the potential to generate rational hy-
potheses with respect to the sequence of symptoms, and
the aetiology and potential treatment of the disease to
be tested in future randomised clinical trials, which have
been called for to develop quality treatment guidelines
[43]. Hopefully this will lead to better strategies to manageeart failure
males (n) SDB (AHI ≥15/h) ß-blocker Spironolactone
51 -* 90% 46%
0 49% 10% 0%
139 51% 85% 62%
68 61% 0% 0%
50 47% 75% 21%
55 -* 82% 58%
26 50% 90% 60%
ng apnea-hypopnea index cixAHI ≥10/h.
Woehrle et al. BMC Cardiovascular Disorders 2014, 14:46 Page 6 of 7
http://www.biomedcentral.com/1471-2261/14/46HF, particularly with respect to effective treatment of
SDB, which in turn will contribute to improved morbidity
and mortality outcomes in these patients.
Conclusions
Registries play an important role in facilitating advances in
the understanding and management of cardiovascular dis-
ease. The SCHLA-HF registry will provide consistent data
on a large group of patients with HF-REF that will demon-
strate aspects of the natural course of the disease and help
to answer questions on the prevalence, risk factors, gender
differences and stability of SDB in these patients.
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